Lemborexant With Sleep Apnea: What Eight Nights Can Tell Us

An insomnia prescription and a sleep-apnea prescription need to be discussed together. If you use a breathing device, bring its name and your sleep-test report when a clinician considers adding a sleeping medicine.

What the crossover study tested

The double-blind trial included 33 people with moderate or severe obstructive sleep apnea, including 10 women. Participants received lemborexant 10 mg and placebo in eight-night periods, in randomized order, separated by at least 14 days. The manufacturer funded the work; four authors were employees.¹

Average breathing-event frequency and oxygen saturation did not significantly differ. At night eight, the AHI difference was −0.8 events per hour, with a 95% confidence interval from −4.9 to 3.3. That interval allows some worsening as well as improvement.¹

Selection matters: screening oxygen saturation had to be at least 94%, and other active respiratory disorders were excluded. Recent CPAP or oral-appliance users were also excluded. This small study cannot establish safety for every person with apnea.¹

What the U.S. warning still says

The DAYVIGO prescribing information includes this trial but states that clinically meaningful respiratory effects cannot be excluded, including during long-term treatment. It directs prescribers to consider respiratory function when treating someone whose breathing is compromised. Eight nights of measurements cannot settle what happens over months.²

The trial’s 10 mg dose is also not an instruction to start there. The label recommends 5 mg initially, with at least seven hours before planned waking; increases depend on response and tolerability. It warns about next-day impairment, including impaired driving in some people taking 10 mg. Alcohol and other sedating medicines can add to its effects.²

For the separate insomnia-outcome comparison, see lemborexant versus zolpidem. A breathing-safety measurement does not establish which prescription will help your insomnia most.

Keep the apnea plan in the conversation

NHLBI explains that CPAP uses air pressure to keep the airway open and should be used whenever you sleep, including naps. It also describes help with mask fit, humidification and pressure settings. Bring problems with those details to the sleep team rather than treating a sleeping pill as a solution to the device problem.³

At the prescribing visit, ask how breathing will be reviewed after starting treatment and which changes should prompt contact. Describe morning grogginess, unintended dozing and any trouble using your existing treatment. Include nonprescription sleep products in the medicine list.

Did I Do That in My Sleep? walks through “The First Treatment Conversation,” including mask discomfort, follow-up and who answers questions after fitting. Use those prompts to coordinate the breathing and insomnia discussions.